MVM Partners LLC Has $9.71 Million Position in MDxHealth SA (NASDAQ:MDXH)

MVM Partners LLC grew its holdings in shares of MDxHealth SA (NASDAQ:MDXH) by 3.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,700,457 shares of the company’s stock after buying an additional 150,000 shares during the period. MDxHealth accounts for approximately 10.6% of MVM Partners LLC’s holdings, making the stock its 2nd biggest position. MVM Partners LLC’s holdings in MDxHealth were worth $9,706,000 at the end of the most recent quarter.

Separately, Perkins Capital Management Inc. boosted its position in shares of MDxHealth by 70.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after purchasing an additional 309,500 shares in the last quarter.

MDxHealth Stock Performance

Shares of NASDAQ MDXH opened at $2.03 on Friday. The company has a 50 day moving average of $2.27 and a 200 day moving average of $2.58. MDxHealth SA has a twelve month low of $1.95 and a twelve month high of $4.64.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.13). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 987.86%. The business had revenue of $23.32 million for the quarter, compared to the consensus estimate of $21.48 million. On average, sell-side analysts forecast that MDxHealth SA will post -1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on MDXH shares. Lake Street Capital assumed coverage on MDxHealth in a research note on Thursday, October 31st. They set a “buy” rating and a $7.00 price objective for the company. Piper Sandler reduced their price target on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.